Body

PITTSBURGH, Aug. 4 – Researchers at the University of Pittsburgh School of Medicine have learned that some healthy people naturally developed an immune response against a protein that is made in excess levels in many cancers, including breast, lung, and head and neck cancers. The finding suggests that a vaccine against the protein might prevent malignancies in high-risk individuals.

WHAT: The Nutrient-Rich Foods (NRF) Index is a new, objective, science-based way to measure the total nutritional quality of foods and beverages.

Elevated cholesterol levels in midlife – even levels considered only borderline elevated – significantly increase the risk of Alzheimer's disease and vascular dementia later in life, according to a new study by researchers at Kaiser Permanente's Division of Research and the University of Kuopio in Finland. The study appears in the journal Dementia & Geriatric Cognitive Disorders.

PHILADELPHIA – How you eat may be just as important as how much you eat, if mice studies are any clue.

Cancer researchers have long studied the role of diet on breast cancer risk, but results to date have been mixed. New findings published in Cancer Prevention Research, a journal of the American Association for Cancer Research, suggest the method by which calories are restricted may be more important for cancer protection than the actual overall degree of calorie restriction.

STANFORD, Calif. —Two common anti-influenza drugs — Relenza and Tamiflu — appear equally effective at preventing common flu symptoms when given before infection, say researchers from the Stanford University School of Medicine. However, data is lacking on the effectiveness and safety of the two drugs in vulnerable groups such as the very young and people with compromised immune systems.

SEATTLE – The latest drug regimens, vaccines and diagnostic tools under development to combat tuberculosis could have a potentially large impact on the disease once they become available, according to research findings published in the Aug. 3 early edition online of the Proceedings of the National Academy of Sciences.

As a fetus does not mount an immune response to maternal proteins that cross the placenta, it has been assumed that a fetus would not reject non–genetically matched blood cells (specifically allogeneic blood cells) if they were transplanted while the fetus was in utero. The hope is that this procedure, which is known as IUHCT, could provide a viable approach for treating congenital blood disorders. However, studies using a mouse model of IUHCT indicate that most fetal recipients of allogeneic blood cells lose their transplanted cells 3-5 weeks after transplantation.